Fleury S.A. (FLRY3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fleury S.A. (FLRY3) has a cash flow conversion efficiency ratio of 0.050x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$264.56 Million ≈ $51.91 Million USD) by net assets (R$5.28 Billion ≈ $1.04 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Fleury S.A. (FLRY3) liquidity interval to measure how many days the company can operate on defensive assets alone.
Fleury S.A. - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Fleury S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fleury S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fleury S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Shenglu Telecommunication Tech Co Ltd
SHE:002446
|
-0.007x |
|
EverCommerce Inc
NASDAQ:EVCM
|
0.045x |
|
Dürr Aktiengesellschaft
F:DUE
|
0.117x |
|
Isiklar Enerji ve Yapi Holding AS
IS:IEYHO
|
-0.116x |
|
Semrush Holdings Inc
NYSE:SEMR
|
0.051x |
|
Dianguang Explosion-proof Technology Co Ltd
SHE:002730
|
-0.019x |
|
Shenzhen Batian Ecotypic Engineering Co Ltd
SHE:002170
|
0.028x |
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
-0.091x |
Annual Cash Flow Conversion Efficiency for Fleury S.A. (2006–2025)
The table below shows the annual cash flow conversion efficiency of Fleury S.A. from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see FLRY3 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | R$5.10 Billion ≈ $999.98 Million |
R$1.57 Billion ≈ $308.32 Million |
0.308x | -14.16% |
| 2024-12-31 | R$5.37 Billion ≈ $1.05 Billion |
R$1.93 Billion ≈ $378.80 Million |
0.359x | +27.54% |
| 2023-12-31 | R$5.11 Billion ≈ $1.00 Billion |
R$1.44 Billion ≈ $282.42 Million |
0.282x | -22.94% |
| 2022-12-31 | R$2.70 Billion ≈ $530.00 Million |
R$987.13 Million ≈ $193.69 Million |
0.365x | -33.47% |
| 2021-12-31 | R$1.85 Billion ≈ $363.88 Million |
R$1.02 Billion ≈ $199.88 Million |
0.549x | +48.61% |
| 2020-12-31 | R$1.75 Billion ≈ $343.55 Million |
R$647.14 Million ≈ $126.98 Million |
0.370x | -11.22% |
| 2019-12-31 | R$1.76 Billion ≈ $345.14 Million |
R$732.32 Million ≈ $143.69 Million |
0.416x | +3.86% |
| 2018-12-31 | R$1.75 Billion ≈ $343.37 Million |
R$701.49 Million ≈ $137.64 Million |
0.401x | +29.17% |
| 2017-12-31 | R$1.71 Billion ≈ $334.85 Million |
R$529.61 Million ≈ $103.92 Million |
0.310x | -11.67% |
| 2016-12-31 | R$1.54 Billion ≈ $301.34 Million |
R$539.57 Million ≈ $105.87 Million |
0.351x | +57.78% |
| 2015-12-31 | R$1.66 Billion ≈ $324.83 Million |
R$368.63 Million ≈ $72.33 Million |
0.223x | +22.60% |
| 2014-12-31 | R$1.57 Billion ≈ $308.64 Million |
R$285.71 Million ≈ $56.06 Million |
0.182x | +46.38% |
| 2013-12-31 | R$1.69 Billion ≈ $331.42 Million |
R$209.59 Million ≈ $41.12 Million |
0.124x | +26.71% |
| 2012-12-31 | R$1.71 Billion ≈ $334.73 Million |
R$167.05 Million ≈ $32.78 Million |
0.098x | +9.49% |
| 2011-12-31 | R$1.63 Billion ≈ $320.20 Million |
R$145.96 Million ≈ $28.64 Million |
0.089x | -19.86% |
| 2010-12-31 | R$1.01 Billion ≈ $198.53 Million |
R$112.92 Million ≈ $22.16 Million |
0.112x | +289.62% |
| 2009-12-31 | R$838.97 Million ≈ $164.62 Million |
R$24.03 Million ≈ $4.72 Million |
0.029x | -93.99% |
| 2008-12-31 | R$151.84 Million ≈ $29.79 Million |
R$72.40 Million ≈ $14.21 Million |
0.477x | -39.20% |
| 2007-12-31 | R$101.35 Million ≈ $19.89 Million |
R$79.48 Million ≈ $15.60 Million |
0.784x | +16.44% |
| 2006-12-31 | R$105.91 Million ≈ $20.78 Million |
R$71.33 Million ≈ $14.00 Million |
0.673x | -- |
About Fleury S.A.
Fleury S.A., together with its subsidiaries, provides diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides health management services, such as telemedicine; orthopedic medicine services; laboratory support; toxicological exam; preventive, integrated solutions, and cli… Read more